Clinical Trial Update: The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

View source ↗

Summary

The trial update reports on the impact of Alna Ocas on nocturia in patients with LUTS suggestive of benign prostatic hyperplasia; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia
• Lower Urinary Tract Symptoms

Drugs mentioned

• Alna Ocas

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Prostatic Hyperplasia | Status: COMPLETED